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The mitochondrial DNA (mtDNA) depletion syndrome is a quantitative defect of mtDNA resulting from dysfunction
of one of several nuclear-encoded factors responsible for maintenance of mitochondrial deoxyribonucleoside tri-
phosphate (dNTP) pools or replication of mtDNA. Markedly decreased succinyl-CoA synthetase activity due to a
deleterious mutation in SUCLA2, the gene encoding the b subunit of the ADP-forming succinyl-CoA synthetase
ligase, was found in muscle mitochondria of patients with encephalomyopathy and mtDNA depletion. Succinyl-
CoA synthetase is invariably in a complex with mitochondrial nucleotide diphosphate kinase; hence, we propose
that a defect in the last step of mitochondrial dNTP salvage is a novel cause of the mtDNA depletion syndrome.
The oxidative phosphorylation (OXPHOS) system con-
sists of 87 proteins that are assembled into five enzymat-
ic complexes. Of the 87 subunits, 13 are encoded by
mtDNA, which also encodes all mitochondrial tRNA
and rRNA transcripts. mtDNA is constantly synthesized
throughout the cell cycle, requiring a balanced supply
of dNTPs within the mitochondria and a large number
of factors, mostly nuclear encoded, that participate in
the replication, transcription, and translation processes.
In the past decade, a growing number of patients with
OXPHOS dysfunction due to depletion of mtDNA have
been reported. The onset of symptoms usually occurs
during the first months of life, and most patients die in
early childhood. Clinical presentation is heterogeneous
and includes progressive muscle weakness, liver failure,
encephalopathy, cardiomyopathy, and renal disease, usu-
ally accompanied by lactic acidemia (Moraes et al. 1991;
Tritschler et al. 1992; Vu et al. 1998; Ducluzeau et al.
1999; reviewed by Elpeleg 2003). Autosomal recessive
inheritance was suspected in many cases, and no mu-
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tations were identified in the mtDNA molecule, which
suggests that mtDNA depletion results from defects in
nuclear factors involved in mtDNA replication. Four
genes have previously been implicated in the patho-
genesis of mtDNA depletion; mutations in the thymidine
phosphorylase gene are associated with leukodystrophy
and gastrointestinal disorder (Nishino et al. 1999); mu-
tations in the deoxyguanosine kinase and mtDNA poly-
merase g genes are associated with encephalopathy and
fatal infantile liver disease (Mandel et al. 2001; Naviaux
and Nguyen 2004); and mutations in the mitochondrial
thymidine kinase gene result in progressive muscle dis-
ease with variable brain involvement (Saada et al. 2001).
We identified a small Muslim pedigree (fig. 1) with
autosomal recessive encephalomyopathy associated with
mtDNA depletion. Patient II-7 is a female, the second
child born to consanguineous parents of Muslim origin.
Her older sister died of neurodegenerative disease at age
7 mo, and her younger sister and brother are healthy.
The pregnancy was uneventful, apart from a markedly
elevated level of a-feto protein in maternal blood. The
patient was born at term but was small for gestation-
al age (weight 2,250 g, !3rd percentile). In early infan-
cy, the patient was irritable, with inconsolable crying.
Psychomotor development was severely retarded, with
marked muscle hypotonia and impaired hearing. She had
frequent respiratory infections, which were thought to
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Figure 1 Family tree, with allele sizes of the microsatellite markers in the critical region on chromosome 13. Only those individuals whose
DNA was available for analysis were annotated. The region of shared homozygosity is shaded. Markers are listed in the left column, and their
physical locations on the chromosome are given (in Mb) in the right column.
be secondary to severe gastroesophageal reflux. Gener-
alized seizures, first noted at age 1 year, were controlled
by valproic acid. Brain MRI performed at age 18 mo
was suggestive of Leigh syndrome, with high signal T2
intensity in the putamen bilaterally and moderate dila-
tation of the lateral ventricles and sulci, compatible with
generalized atrophy. Physical examination at age 7 years
revealed contractures at the knee and hip joints and dys-
tonic posturing of the fingers. The patient was able to
roll over but was unable to sit unsupported. At age 7
years, she recognized and greeted her relatives with a
smile and cried when being scolded but had neither
speech nor gestures. She had mild ptosis, but her vision
appeared intact. The patient’s hearing was impaired, but
this condition was not assessed any further. Chronic mi-
crocytic anemia (hemoglobin level [Hb] 9.1 g/dl; mean
corpuscular volume [MCV] 65 femtoliters [fl]) and an
elevated lactate level in plasma (4.3 mM; normal level
is !2.1 mM) were present. Liver and renal function tests,
plasma creatine kinase level, abdominal ultrasound, elec-
trocardiogram, and echocardiogram were normal.
Patient II-6 is the cousin of II-7 and is the seventh
child born to consanguineous parents. An older brother
had a cot death at age 4 mo. The patient was born at
term but was small for gestational age (weight 2,180 g,
!3rd percentile). At age 2 mo, he was found unrespon-
sive and hypopneic. Electroencephalogram showed gen-
eralized slow activity, and CT scan of the brain revealed
lacunar infarcts in the basal ganglia. The patient slowly
regained consciousness and, after 2 d of assisted venti-
lation, started breathing spontaneously, but his subse-
quent development was poor. Echocardiogram was nor-
mal. At age 1 year, there was generalized muscle hypo-
tonia, lack of voluntary movements, and bilateral hear-
ing loss. A generalized seizure disorder, first noted at age
3 years, was controlled by clonazepam. At age 5 years,
the patient’s condition was unchanged, with severe psy-
chomotor retardation and prominent muscle hypotonia.
He had microcytic anemia (Hb 11.1 g/dl; MCV 65 fl)
and an elevated lactate level in plasma (4–5 mM), but
his liver and renal function tests and plasma creatine
kinase level were normal.
The enzymatic activities of the OXPHOS complexes
I–V in muscle mitochondria were determined by stan-
dard spectrophotometric methods (Hoppel and Cooper
1969; Dooijewaard and Slater 1976). The activities of
complexes I and IV were significantly decreased, and
complexes III and V were less affected, whereas complex
II, the only complex that does not contain mtDNA-en-
coded proteins, was borderline normal (table 1). It is no-
table that the pathological and histochemical examina-
tions of the muscle tissue from the two patients showed
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Table 1
Activity of the Enzymatic Complexes of the Mitochondrial Respiratory Chain in Mitochondria Isolated from Muscle and Fibroblasts
TISSUE AND SUBJECT(S)
CITRATE SYNTHASE
ACTIVITY
ACTIVITY OF ENZYMATIC COMPLEXa
I IIII IIIII II IV V
Muscle mitochondria:
Patient II-7 1,780 127 (52%) 148 (28%) 202 (72%) 255 (87%) 409 (35%) 501 (83%)
Patient II-6 1,790 107 (43%) 134 (25%) 181 (64%) 211 (72%) 307 (26%) 351 (58%)
Controls ( ):np 50
Mean  SD 1,990  370 274  127 586  234 312  118 327  52 1,326  501 645  203
Range 1,320–2,900 115–503 305–999 192–531 255–442 829–2,300 222–1,002
Fibroblast mitochondria:
Patient II-7 199 23 (93%) ND 82 (78%) 44 (59%) 335 (101%) ND
Controls ( ):np 27
Mean  SD 249  97 31  11 ND 131  44 81  31 412  59 ND
Range 135–415 15–38 ND 63–204 50–101 203–586 ND
a Values are given in nmol/min/mg of protein. For patients, the percentage of the control mean normalized for citrate synthase activity is
shown in parentheses. ND p not determined.
unremarkable results. The activities of all OXPHOS com-
plexes were normal in mitochondria isolated from fibro-
blasts (table 1). The findings in muscle mitochondria sug-
gested a defect in the synthesis of the mtDNA-encoded
proteins. Sequence analysis of muscle mtDNA excluded
mutations in the 22 mitochondrial tRNA genes in patient
II-7. Southern blot analysis of muscle DNA, performed
as described elsewhere (Saada et al. 2001), revealed a
normal-size band of mtDNA in both patients, but the
ratio of mtDNA to nuclear DNA, determined by real-
time PCR, was reduced to 32% of the mean control value.
The mtDNA:nuclear DNA ratio in fibroblasts was 95%
of the mean control value.
Genomic DNA was extracted from blood samples
from the two patients and 10 unaffected family mem-
bers, after informed consent was obtained from the sub-
jects or their guardians. To localize the mutated gene in
this family, we performed a genomewide screen to search
for homozygosity by using polymorphic microsatellite
markers with an average intermarker distance of 10 cM
(ABI PRISM Linkage Mapping Set MD10, version 2.0
[Applied Biosystems]). Genotypes were obtained for 402
markers, of which 21 were homozygous in both patients.
Five of these markers were located successively on an
∼50-Mb fragment of chromosome 13, bordered by
markers D13S175 and D13S156. Additional markers
from other mapping sets and other selected polymorphic
dinucleotide repeat markers were genotyped, which en-
abled us to exclude all other chromosomal regions and
to narrow the shared homozygosity region to 20 Mb on
chromosome 13, bordered by (but excluding) markers
D13S263 and D13S801 (fig. 1). Mitochondrial locali-
zation was predicted (score 160) in only 3 of 113 ORFs
in this region, by use of the MitoP2 prediction program:
ORFs encoding the b chain of the ADP-forming succinyl-
CoA ligase (SUCLA2 [MIM 603921, NCBI accession
number NM_003850]), a hypothetical protein FLJ25853,
and the copper-transporting ATPase 2 (ATP7B) associated
with Wilson disease (Andreoli et al. 2004). Sequence anal-
ysis of the 12 exons of the SUCLA2 gene (Homo sapi-
ens chromosome 13, nt 47414793–47473463 [NCBI ac-
cession number NC_000013.9]) and their exon-intron
boundaries (primer sequences available on request) re-
vealed a complex genomic rearrangement at the 3′ end of
exon 6, with a homozygous deletion of 43 nt, encom-
passing the last 14 nt of exon 6 and the first 29 nt of
IVS6, and an insertion of 5 nt (32720del43ins5) (fig. 2A).
Analysis of the SUCLA2 cDNA by use of primers cF1
(5′-TTCAAAAGATGTCTGATAAAGG-3′) and cR1 (5′-
CGCATGATTCCTCCAAAAATGT-3′) resulted in two
amplification products of nearly equal abundance, both
of which skip exon 6 and one of which also lacks the
first 74 bp of exon 7 (fig. 2B). Analysis of the genomic
PCR products from the other family members, by use of
exon/intron 6 primers 6F1 (5′-GTTGATTAGACATATG-
CAAACTACCT-3′) and 6R2 (5′-AGGGAAGCATATTA-
GAGAAATAAATG-3′), confirmed that all available rel-
atives are heterozygous for the rearrangement, except for
individual II-5, who is homozygous for the wild-type se-
quence. Using the same primer set, we analyzed 105 anon-
ymous Muslim Arabs for the presence of the mutation
and found no carriers.
The SUCLA2 gene spans nearly 60 kb and encodes
the 463 amino acids of the b subunit of the ADP-forming
succinyl-CoA synthetase (SCS-A) (Allen and Ottaway
1986; Weitzman et al. 1986). This mitochondrial matrix
enzyme catalyzes the formation of succinate and ATP
from succinyl-CoA and ADP in the tricarboxylic acid
(TCA) cycle in a reversible manner. SCS-A is a hetero-
dimer that shares its a subunit with another mitochon-
drial matrix succinyl-CoA synthetase, SCS-G, which uses
GDP (Sanadi et al. 1954). Thus, the two enzymes, SCS-
G and SCS-A, catalyze a similar reaction by using dif-
ferent phosphate donors, with their b subunits deter-
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Figure 2 A, Genomic sequence of the exon 6–IVS6 junction of the SUCLA2 gene in patient II-7 and her mother, I-4 (upper and lower
chromatograms, respectively). The deleted 43 nt are shown in italics, and the 14 exonic nucleotides are also capitalized. The deletion start site
is indicated by an arrow. The inserted 5 nt are shown in bold and are followed by the normal IVS6 sequence. B, SUCLA2 cDNA sequence of
patient II-7. A schematic representation (g) shows the exon-intron organization around the mutation site, which is shown in black. With the
use of primers cF1 and cR1, two amplification products (c1 and c2) were seen, both of which skip exon 6, and transcript c2 also lacks the
first 74 bp of exon 7. The splicing site of exon 5 with mid-exon 7 is indicated by an arrow.
mining the nucleotide specificity (Johnson et al. 1998a,
1998b). Notably, the activity of both SCS-G and SCS-
A is considerable in mitochondria from rat liver, kidney,
and heart, but SCS-A, the ADP-forming enzyme, pre-
dominates in the brain (Lambeth et al. 2004).
Exon 6 of the SUCLA2 gene is composed of 139 nt
and encodes 47 amino acids (residues 221–267) that form
the ATP grasp domain of the protein. Skipping exon 6 is
likely to result in the synthesis of the first 221 amino acids,
followed by 50 residues of a different reading frame. Since
the CoA-ligase domain is created by residues 305–441,
truncated polypeptide chains are likely to adversely affect
the catalytic activity. The shorter transcript, lacking exon
6 as well as the first part of exon 7, remains in-frame and
is predicted to lead to the absence of 71 residues, starting
at amino acid 221 but preserving the CoA-ligase domain.
Accordingly, SCS-A activity in muscle mitochondria from
patient II-6, determined in the direction of succinyl-CoA
formation (Cha and Parks 1964), was decreased to 0.038
U per mg of mitochondrial protein (U/mg) (the average
control value from six healthy children who underwent
orthopedic surgery was 0.210 U/mg; range 0.18–0.25 U/
mg). In contrast, the activity of SCS-G in the patient’s
muscle mitochondria was 0.408 U/mg (average con-
trol value 0.386 U/mg; range 0.31–0.41 U/mg; ).np 6
Thus, the ratio of SCS-A to SCS-G activity in mitochon-
dria isolated from the patient muscle was reduced to
17% of the control value. The activity of SCS-A was nor-
mal in mitochondria isolated from muscle of a patient
with markedly decreased activities of complexes I and
IV due to a high load of the A3243G mutation in the
tRNALeu(UUR) gene, indicating that impaired OXPHOS
activity does not perturb the function of SCS-A.
How does a mutation in the SUCLA2 gene cause
mtDNA depletion? The gene product of the LSC1 gene,
which is the yeast homologue of the SUCLA1 gene, is
a component of the yeast mtDNA nucleoid (Chen et al.
2005). Defects in some nucleoid proteins in humans,
such as the mtDNA polymerase, the mitochondrial sin-
gle-stranded DNA-binding protein, and the adenine nu-
cleotide translocator 1, were associated with mtDNA
depletion or multiple mtDNA deletions. However, the
gene product of LSC2, the yeast homologue of SUCLA2,
was not shown in nucleoids, and none of the succinyl-
CoA synthase subunits was identified in the mtDNA
nucleoids in higher eukaryotes (Bogenhagen et al. 2003).
A plausible explanation is offered by the finding that
SCS-A copurifies and is tightly associated in a complex
with nucleoside diphosphate kinase (NDPK) in both pro-
karyotes and eukaryotes (Kadrmas et al. 1991; Kavan-
augh-Black et al. 1994; Kowluru et al. 2002). NDPKs
are ubiquitous protein kinases that also catalyze the
exchange of terminal phosphates between tri- and di-
phosphoribonucleosides and are crucial for maintain-
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ing the homeostasis of ribonucleotides and deoxyribo-
nucleotides (Parks and Agarwal 1973). Specifically, mito-
chondrial deoxyribonucleotide diphosphates are phos-
phorylated by a mitochondrial NDPK, NM23-H4 (Milon
et al. 2000). The importance of this salvage pathway step
for mtDNA synthesis is underscored by the lack of de
novo synthesis of dNTPs in this organelle and by the
constant need for building blocks for mtDNA synthesis
throughout the whole cell cycle (Bogenhagen and Clayton
1976; reviewed by Saada 2004).
Whereas the physical proximity of succinyl-CoA syn-
thetase (SCS) and NDPK is indisputable, the functional
significance of their coexistence in a complex is less clear.
It was proposed that this proximity signals the involve-
ment of NDPK in energy metabolism, possibly by di-
rectly activating the SCS by phosphorylation (Kowluru
et al. 2002). Our data suggest that SCS activity is essen-
tial for mtDNA synthesis and that SCS deficiency results
in mtDNA depletion, possibly because of secondary
NDPK dysfunction. Whether such an interference in-
volves the nucleotide triphosphate donation or a con-
formational change induced by the SCS protein is pres-
ently unknown. Regardless of the precise mechanism,
the brain seems to be the most vulnerable tissue, not
only because all of its SCS activity can be attributed to
the SCS-A enzyme, but also because the mitochondrial
NDPK is hardly expressed in the human brain (Milon et
al. 1997) and because of the rate-limiting role of NDPK
in mtDNA replication in postmitotic tissues (Bradshaw
and Samuels 2005). The fact that other tissues, such as
liver, kidney, and heart, are not affected in our patients
suggests that the nature of the interaction between SCS
and NDPK is not influenced by the specific phosphate
donor.
Genetic defects of the TCA cycle are uncommon in
humans, and the most severe defects are probably lethal
in early gestation (Rustin et al. 1997). Deficiency of SCS-
A in our patients is compatible with life, likely because
of the presence of SCS-G, an enzyme with an overlapping
activity. For some of the TCA cycle proteins, additional
cellular roles beyond their catalytic activities in the cy-
cle have been proposed (Jeffery 1999). For example, fu-
marase and succinate dehydrogenase act as tumor sup-
pressors in humans (Baysal et al. 2000; Tomlinson et al.
2002). Our finding that SCS-A deficiency is associated
with mtDNA depletion in humans parallels the essential
role of aconitase in mtDNA maintenance in yeast (Chen
et al. 2005), and both highlight yet another pathway in
which TCA cycle enzymes are involved.
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